Patients with no psoriasis risk allele may still benefit from ustekinumab
Being positive for the psoriasis risk allele is associated with a better response to ustekinumab therapy in patients with plaque psoriasis — but those with negative findings also do well, a meta-analysis shows.
Dutch researchers reviewed eight studies involving more than 1000 patients. All of the studies investigated the link between having the psoriasis risk allele (HLA-C*06:02) and a 75% improvement in the Psoriasis Area and Severity Index (PASI75) in response to ustekinumab therapy.
At six months, PASI75 evaluation by